NCT06956755 Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
| NCT ID | NCT06956755 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Groupe Francophone des Myelodysplasies |
| Condition | Myelodysplastic Syndromes |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,990 participants |
| Start Date | 2003-07-07 |
| Primary Completion | 2030-01-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,990 participants in total. It began in 2003-07-07 with a primary completion date of 2030-01-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Registry MDS is an ongoing, observational study that has collected longitudinal data on diagnostics, demographics, clinical parameters, and health Care Interventions (HCI) from patients with MDS and therapy-related acute myeloid leukemia
Eligibility Criteria
Inclusion Criteria: * Male or female * Age \> 18 years * Patients with myelodysplastic syndrome and therapy-related acute myeloid leukemia * Able and willing to provide written informed consent Exclusion Criteria: * Age \<18 years * Patient is unwilling or unable to give consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06956755 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myelodysplastic Syndromes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06956755 currently recruiting?
Yes, NCT06956755 is actively recruiting participants. Contact the research team at fatiha.chermat-ext@aphp.fr for enrollment information.
Where is the NCT06956755 trial being conducted?
This trial is being conducted at Rouen, France.
Who is sponsoring the NCT06956755 clinical trial?
NCT06956755 is sponsored by Groupe Francophone des Myelodysplasies. The trial plans to enroll 6,990 participants.